Sage Therapeutics Inc
Company Profile
Business description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Contact
55 Cambridge Parkway
CambridgeMA02142
USAT: +1 617 299-8380
E: Jeff.Boyle@sagerx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
487
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,157.90 | 0.80 | -0.01% |
| CAC 40 | 8,060.26 | 17.31 | 0.22% |
| DAX 40 | 23,007.93 | 116.25 | 0.51% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,664.49 | 17.70 | 0.20% |
| HKSE | 23,905.56 | 215.84 | 0.91% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,608.49 | 68.57 | -0.18% |
| NZX 50 Index | 12,128.21 | 14.67 | 0.12% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,936.90 | 5.70 | 0.07% |
| SSE Composite Index | 3,370.03 | 5.20 | 0.15% |